Compare Johnson & Johnson (JNJ) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Liberty Global Ltd Class C — how do they compare? Johnson & Johnson trades at $260.45 (market cap $618.09B), while Liberty Global Ltd Class C trades at $8.43 (market cap $3.06B). The key difference: Johnson & Johnson is far larger — about 202× Liberty Global Ltd Class C's market cap, and Johnson & Johnson pays a 2.09% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Liberty Global Ltd Class C for 21 Days on average.
| JNJ | LBTYK | |
|---|---|---|
Market Cap | $618.09B | $3.06B |
Volume | 6,050,983 | 2,508,956 |
Sector | Health | Media |
52-Week High | $278.43 | $12.67 |
52-Week Low | $186.00 | $8.75 |
Typical Hold Time | 129 Days | 21 Days |
Enterprise Value | $646.37B | $9.72B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
LBTYK trades at $8.65, down 3.03% today and near 52-week lows. The stock shows bearish technical signals with negative earnings trends, including a Q3 2026 net loss of -$3.0B. However, strong analyst support (69% buy ratings) and a $12.67 price target suggest potential upside. Recent developments include the Ziggo Group spin-off preparation and AI partnership with Sierra.
The outlook remains cautious due to persistent losses and bearish technicals, but strategic moves like Ziggo's 2027 listing and solid cash flow ($602M net in 2026) offer recovery potential. Key risks include execution challenges and competitive pressures, while institutional sentiment provides a floor for valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
